PDF icon PDF herunterladen
Semin Liver Dis 2019; 39(01): 043-052
DOI: 10.1055/s-0038-1676098
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines?

Melody J. Xu
1   Department of Radiation Oncology, University of California San Francisco, San Francisco, California
,
Mary Feng
1   Department of Radiation Oncology, University of California San Francisco, San Francisco, California
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. Dezember 2018 (online)

   Lizenzen und Reprints
Preview

Abstract

Hepatocellular carcinoma (HCC) is a complex and diverse disease, with choice of treatment dependent on a patient's disease burden, location of disease, underlying liver function, and performance status. While radiation therapy (RT) was historically omitted from treatment algorithms, immense technological advances over the past several decades have enabled introduction of RT as an effective and safe treatment option for patients with HCC. Growing prospective and retrospective evidence supports the use of RT, particularly stereotactic body radiotherapy (SBRT), for a wide range of indications in HCC from locally advanced unresectable disease to bridge therapy for liver transplant candidates. SBRT is associated with excellent local control, even for patients refractory to or ineligible for other forms of locoregional therapy. Treatment is well-tolerated and associated with low rates of severe toxicity. Randomized trials are needed to define the role of SBRT in HCC treatment relative to other established locoregional treatments.

Keywords

hepatocellular carcinoma - stereotactic body radiotherapy - radiation therapy - review